Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
about
Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonistsShould the PANSS be rescaled?Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population.Paliperidone: the evidence of its therapeutic value in schizophrenia.Cytochrome P450 polymorphisms and response to antipsychotic therapy.Optimizing dosing in atypical neuroleptic monotherapyMetabolic drug interactions with new psychotropic agents.Clinical pharmacology of atypical antipsychotics: an update.Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypesRelationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalentsMetabolic drug interactions with newer antipsychotics: a comparative review.Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE studyPharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.Newer antipsychotics: comparative review of drug interactions.The analysis of antipsychotic drugs in human matrices using LC-MS(/MS).The pharmacology and formulation of paliperidone extended release.Atypical antipsychotics: revolutionary or incremental advance?Pharmacokinetic patterns of risperidone-associated adverse drug reactions.Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone.Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia.Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.Influence of age and gender on risperidone plasma concentrations.Intramuscular aripiprazole in the acute management of psychomotor agitation.Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia.Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults.Elevated risperidone serum concentrations during acute inflammation, two cases.Research Highlights
P2860
Q24656286-AD0160E4-0935-448C-8188-FAC2A1217C33Q33890074-89AC49D7-3398-41D3-B1CE-2F2D164F8C02Q34273450-3AEB208E-6343-4CE1-A5EC-CA76D07DB1BEQ34449894-C2882B71-31E9-4EE5-A560-8B18653DB961Q34612118-A2A202DB-425D-4550-B7BE-94C65CABB607Q35236514-F5DEC4B5-0837-41EE-B314-316A352772A2Q35619640-04E9A08E-D363-4EBE-988D-625F95004AB7Q35728228-0399FA5B-194C-4438-A585-0F57B689CD9DQ35826139-1DF7FAF1-BF08-4FDF-94C9-9CFC73F72078Q35847706-EC3009D2-5C36-448A-8A26-19CC1DDAC247Q36120821-330254FB-7929-44B3-94D4-1B85F29016A0Q36233555-296B4D20-68A0-4832-B37E-FF47EC88AFD1Q36235106-959D1440-797E-4789-87C9-A97BEA03D614Q36703845-365180B0-9B52-487B-8E27-EE1615D470BAQ37142429-66D3B07E-A249-4205-B1E5-3298A460873FQ37488898-E9445001-B701-47B6-BEDE-B9697E9BC205Q37610290-FD6D8DEB-74FA-4C51-B240-0008C071A064Q38008991-64B6DB4D-0F37-460B-A182-C163CFC731F1Q38067139-9DCA19EA-04D4-49EC-98DC-16D8FA2492F9Q39412178-A19803F4-E196-439F-9D29-050EF513AE54Q39633628-52EBD53B-5EC7-4825-BF8C-4FB53B459916Q40780592-421B264A-D8CF-4999-968B-AE468E31D1D9Q43120631-ACE30A26-CEE2-4B62-879E-2F12DDE133FEQ44343565-2DB2C443-9877-4D2D-B502-D7438175C0F5Q44792438-C1479694-0466-41FF-87E2-A3E7454EF448Q44936215-CC46A520-1D38-4ACB-9E31-084561550D8AQ45991893-258CDFBA-E0D8-458F-ACAA-266B10880CD4Q46570350-DC28C479-3380-4420-BB67-4F338582CF40Q46703897-6F5DF79D-FD0C-4632-9CE2-33DCE2E7CBFEQ46953729-1CCD4D8D-3277-44B3-A2A4-64F7CD68CA52Q47935625-7C8FEF96-DFDE-45A8-8D74-4CED12AB862EQ50973731-9BD3A46A-D266-47B5-BCFD-0EEED3FEDC11Q57585792-BE6DEA5D-FF9D-440F-8E9C-A5AD3B32981B
P2860
Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Relationship between plasma ri ...... n patients with schizophrenia.
@ast
Relationship between plasma ri ...... n patients with schizophrenia.
@en
type
label
Relationship between plasma ri ...... n patients with schizophrenia.
@ast
Relationship between plasma ri ...... n patients with schizophrenia.
@en
prefLabel
Relationship between plasma ri ...... n patients with schizophrenia.
@ast
Relationship between plasma ri ...... n patients with schizophrenia.
@en
P2093
P356
P1433
P1476
Relationship between plasma ri ...... n patients with schizophrenia.
@en
P2093
Facciolà G
P2888
P304
P356
10.1007/S002130000576
P577
2001-01-01T00:00:00Z
P6179
1027668471